CD19 chimeric antigen receptor T cell therapy

Drug Profile

CD19 chimeric antigen receptor T cell therapy

Alternative Names: CD19 CAR T Cells

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator VCANBIO Cell and Gene Engineering
  • Developer Institute of Hematology & Blood Diseases Hospital; VCANBIO Cell and Gene Engineering
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater) in China (IV) (NCT02975687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top